Clinical trials: Ischemia, Brain
Ischemic Stroke, Acute
MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure
The use of metabolic modulators creates prospects for increasing the efficiency of the rehabilitation treatment of patients with acute cerebral failure
- Trial name
- NCT06221826
- Testing
- Mexidol
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Pharmasoft
Acute Ischemic Stroke
Hypothermia in Acute Stroke With Thrombolysis Imaging Evaluation of Revascularization
The primary objective of this Phase 2 HASTIER study, as an ancillary study to ICTuS 2, is to compare key imaging measurements for serial changes in recanalization and reperfusion between hypothermia and normothermia treatment…
- Trial name
- HASTIER (NCT01778855)
- Testing
- IV t-PA and normothermia, IV-tPA and hypothermia
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of California, Los Angeles
Left Atrial Appendage Exclusion
AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery
Prospective, non-randomized trial to evaluate the safety and efficacy of the LAA Exclusion Device (Clip) for the exclusion of the LAA via epicardial tissue approximation.
- Trial name
- EXCLUDE (NCT00779857)
- Testing
- AtriCure LAA Exclusion System
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- AtriCure, Inc.
Acute Ischemic Stroke
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) natalizumab reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) in participants with acute…
- Trial name
- ACTION (NCT01955707)
- Testing
- natalizumab
- Where
- 50 sites in United States, Germany and 1 more
- Volunteers
- 161 people
- Sponsor
- Biogen
Stroke, Rhabdomyolysis
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
This trial will be a phase 2 randomized safety study in which ischemic stroke patients will be randomly assigned within 24 hours of symptom onset to placebo or standard dose lovastatin versus short-term high-dose lovastatin 640…
- Conditions
- Stroke, Rhabdomyolysis, Jaundice
- Trial name
- NeuSTART2 (NCT01976936)
- Testing
- Low Dose Lovastatin, High Dose Lovastatin
- Where
- 7 sites in United States
- Volunteers
- 162 people
- Sponsor
- Columbia University
Acute Stroke, Brain Ischemia
The Capillary Index Score Trial
This study seeks to investigate the capillary index score (CIS) to further improve patient selection of endovascular treatment (EVT) in acute ischemic stroke (AIS).
- Conditions
- Acute Stroke, Brain Ischemia, Ischemic Stroke
- Trial name
- NCT02618031
- Testing
- Endovascular Treatment (EVT)
- Where
- 6 sites in United States
- Volunteers
- 57 people
- Sponsor
- Firas Al-Ali
Stroke, Ischemic Stroke
Safety Study of Post Intravenous tPA Monitoring in Ischemic Stroke
Intravenous (IV) tissue plasminogen activator (tPA) is the only FDA-approved therapy for treatment of acute ischemic stroke. In the United States, IV tPA is typically administered in the Emergency Department (ED) for patients…
- Trial name
- OPTIMIST (NCT02039375)
- Testing
- "Hopkins" post tPA for ischemic stroke monitoring protocol
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Johns Hopkins University
Coronary Artery Disease
Observational Study of OCT in a Patients Undergoing FFR
The purpose of this study is to define and evaluate optical coherence tomography (OCT) stent guidance parameters through prospective data collection in percutaneous coronary intervention (PCI) procedures of de novo lesions.
- Trial name
- ILUMIEN I (NCT01663896)
- Testing
- OCT stent guidance
- Where
- 36 sites in United States, Australia and 12 more
- Volunteers
- 418 people
- Sponsor
- Abbott Medical Devices
Acute Coronary Syndrome, TIA
Early Psychological Intervention to Prevent Cardiovascular Event-Induced PTSD (REACH Sub-study)
The overall purpose of this project is to determine the feasibility of conducting a randomized clinical trial that compares written exposure therapy with usual care among patients at risk for cardiovascular event-induced PTSD.
- Conditions
- Acute Coronary Syndrome, TIA, Stroke, Cardiac Arrest
- Trial name
- NCT03605693
- Testing
- Written Exposure Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Stroke
Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
The objective of this study is to find out if Chinese Acute Ischaemic Stroke (AIS) patients older than 80 years benefit from intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) treatment within 4.5 hours of symptom…
- Trial name
- NCT05401149
- Testing
- rt-PA
- Where
- China
- Volunteers
- 3,058 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
Prospective Evaluation to Characterize the Real-World Performance of the EMBOVAC Aspiration Catheter
A post-market study evaluating the EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
- Trial name
- PERFECT (NCT04531904)
- Testing
- EMBOVAC Aspiration Catheter
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 102 people
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
Cerebral Infarction
Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)
The study is designed to assess safety of Vorapaxar when added to standard of care (aspirin) in Japanese subjects with cerebral infarction.
- Trial name
- NCT00684515
- Testing
- Vorapaxar 2.5 mg, Vorapaxar 1 mg, Aspirin 75-150 mg
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Stroke, Ischemia
Analysis of Revascularization in Ischemic Stroke With EmboTrap
The study objective is to examine the recanalization efficacy of the EmboTrap device and its associated performance characteristics and to record associated clinical outcomes in a manner that facilitates relevant comparison of…
- Trial name
- ARISEII (NCT02488915)
- Testing
- EmboTrap® Revascularization Device
- Where
- 12 sites in United States, Belgium and 2 more
- Volunteers
- 228 people
- Sponsor
- Neuravi Inc.